<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392753</url>
  </required_header>
  <id_info>
    <org_study_id>17/LO/1457</org_study_id>
    <nct_id>NCT03392753</nct_id>
  </id_info>
  <brief_title>Mechanochemical Ablation Compared to Cyanoacrylate Adhesive</brief_title>
  <official_title>Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be comparing the treatment of varicose veins using either mechanochemical
      ablation (MOCA) or cyanoacrylate adhesive (CAE). Patients will be randomised to receiving
      either MOCA or CAE.

      The pain scores, clinical scores, quality of life scores, occlusion and re-intervention rate
      at 2 weeks, 3, 6 and 12 months as well as the cost effectiveness of each intervention will be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised clinical trial comparing MOCA to CAE. Patients will be randomised
      into group A (MOCA) or group B (CAE). Only the endovenous ablation part of the procedure will
      be randomised while the decision as to whether patients should receive treatment of their
      varicose tributaries will be at the discretion of the clinical team.

      The device used for MOCA (group A) will be the ClariVein® mechanochemical ablation (MOCA)
      device (Vascular Insights, Madison, CT, USA).

      The device used for CAE (group B) will be the VenaSealTM Closure System (Medtronic,
      Minneapolis, Minnesota, USA).

      Re-intervention of the treated saphenous veins will not be decided until at least 3 months
      after their initial procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">November 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>An internet-based randomisation service will be used Outcome assessors will be blinded as to treatment offered</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score during ablation</measure>
    <time_frame>On day 0</time_frame>
    <description>Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score at the end of the procedure</measure>
    <time_frame>On day 0</time_frame>
    <description>Pain score at the end of the procedure using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Using the EuroQoL's EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Aberdeen Varicose Vein Questionnaire (AVVQ) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Using the CIVIQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical change</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical change</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Venous Clinical Severity Score (VCSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score over the first 10 days</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of bruising at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal activities</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>Mechanochemical ablation (MOCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyanoacrylate adhesive (CAE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanochemical ablation</intervention_name>
    <description>Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)</description>
    <arm_group_label>Mechanochemical ablation (MOCA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cyanoacrylate adhesive</intervention_name>
    <description>Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)</description>
    <arm_group_label>Cyanoacrylate adhesive (CAE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18 years of age

          -  Symptomatic GSV or SSV vein reflux &gt; 0.5 seconds on colour Duplex

        Exclusion Criteria:

          -  Current DVT

          -  Recurrent varicose veins

          -  Arterial disease (ABPI&lt;0.8)

          -  Vein diameter &lt; 3mm

          -  Patient who are unwilling to participate

          -  Inability or unwillingness to complete questionnaires

          -  Adverse reaction to sclerosant or cyanoacrylate

          -  Not been involved in another venous trial for at least 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alun H Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amjad Belramman</last_name>
    <phone>02033117335</phone>
    <email>a.belramman17@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roshan Bootun</last_name>
    <phone>02033117335</phone>
    <email>r.bootun@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charing Cross Hospital, Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amjad Belramman</last_name>
      <phone>+442033117335</phone>
      <email>a.belramman17@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Roshan Bootun</last_name>
      <phone>+442033117335</phone>
      <email>r.bootun@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alun H Davies</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tristan RA Lane</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roshan Bootun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amjad Belramman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tjun Y Tang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

